ClinicalTrials.gg
CompletedNCT04818918FloVitaUpdated Oct 22, 2026

Coronary Flow and Myocardial Viability: the FloVITA Study

An observational study in Myocardial Infarction and Myocardial Ischemia, sponsored by Centre Hospitalier Universitaire de Besancon. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

How we know

Updated Oct 22, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 168 studies in Myocardial Infarction with a site in France — 22 open to participants now, 31 under way, 7 of them phase 3. Myocardial Infarction · France.

Enrollment
50th of 54
40 · median 756
Started
2021
with 10 others
Observational
54 of 168
9 open now
Registered
131st of 168
by date

Among the 168 studies in Myocardial Infarction with a site in France, this one is the 50th largest by enrollment of the 54 observational ones that give a count, is one of 11 that started in 2021, is one of 54 observational ones, and was the 131st registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

22 of the 168 studies in Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Myocardial Infarction with a site in France, or all of them as a file.
02

Study summary

Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value >0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass.

Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI.

In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.

03

Conditions studied

  • Myocardial Infarction
  • Myocardial Ischemia

Keywords

  • microvascular resistance
  • fractional flow reserve
  • myocardial viability
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with recent (>=7 days) ST segment elevation MI for the intervention group, and patients with stable angina or silent ischemia for the control group.

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria for the STEMI group:

    • ST segment elevation MI ≥7 days treated by angioplasty of the left anterior descending (LAD) artery
    • Scheduled to undergo angiography for fractional flow reserve (FFR) assessment of a lesion other than the infarct-related artery.
  • Inclusion criteria for the control group:

    • patients undergoing non-urgent coronary angiography for stable angina or silent ischemia
    • with measure of the FFR on one or more vessels (intermediate lesion \<90% without proven ischemia)
  • absence of any significant lesion on the LAD (as assessed by angiography or FFR>0.8)
  • Inclusion criteria for both groups:

    • Written
    • Affiliation to a social security regimen (or beneficiary thereof).

Exclusion Criteria:

  • Target vessel (LAD) not permeable.
  • FFR \<0.8 in the LAD
  • Coronary spasm
  • \<0.50 or a history of anterior MI in patients in the control group
  • Hypertrophic cardiomyopathy
  • Severe valvular heart disease
  • History of coronary artery bypass graft
  • Patients with limited legal capacity or patients under guardianship/tutorship
  • Patients with anticipated poor compliance as assessed by the investigator
  • Patients not affiliated to any social security regime.
  • Pregnant women.
  • Subjects within the exclusion period of another clinical trial as noted in the national registry of research volunteers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • STEMI group

    Patients with anterior ST segment MI treated with percutaneous coronary intervention of the left anterior descending artery, at least 7 days prior to inclusion, and scheduled for new angiography to evaluate FFR of a lesion other than the infarct-related artery. Absolute coronary flow and microvascular resistance will be measured in the LAD.

    Device: Absolute coronary flow measurement · Device: Microvascular resistance measurement · Other: Cardiac MRI

  • Control group

    Patients undergoing non-urgent coronary angiography for stable angina or silent ischemia, with measure of FFR on one or more vessels (intermediate lesions \<90% without proven ischemia). Absence of any signfiicant lesion on the left anterior descending artery (as evaluated by angiography or FFR value \>0.8). Absolute coronary flow and microvascular resistance will be measured in the LAD.

    Device: Absolute coronary flow measurement · Device: Microvascular resistance measurement

Interventions

  • DeviceAbsolute coronary flow measurement

    Absolute coronary flow will be measured.

  • DeviceMicrovascular resistance measurement

    Microvascular resistance will be measured.

  • OtherCardiac MRI

    Cardiac MRI will be performed to evaluate myocardial viability.

06

What researchers measure

Primary outcomes

  1. Coronary flow (mL/min) in the LAD

    Measurement of coronary flow in mL/min in the left anterior descending artery

    Time frame: At the end of the angiography procedure

Secondary outcomes

  1. Microvascular resistance

    Measurement of microvascular resistance in the LAD

    Time frame: At the end of the angiography procedure

  2. Myocardial necrosis

    Extent of myocardial necrosis on cardiac MRI (number of segments)

    Time frame: Cardiac MRI to be performed 7 to 30 days after index angiography procedure

07

Study locations

1 site
  • CHU Besancon
    Besançon, 25000, France
08

References and documents

Publications

  • Guillon B, Besutti M, Revel L, Seronde MF, Meneveau N, Chopard R. Absolute Coronary Flow Reduction Mediated by Microvascular Resistance in Myocardial Infarction: The FLOVITA Study. Catheter Cardiovasc Interv. 2025 Dec;106(7):3588-3596. doi: 10.1002/ccd.70268. Epub 2025 Oct 13. PubMed 41078218 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Aug 2025, 51 months.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's 51 months is close to that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Aug 2024 → Aug 2025 and completion Aug 2024 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 26, 2021
StartActual
May 19, 2021
Primary completionActual
Aug 20, 2025was Aug 2024
CompletionActual
Aug 20, 2025was Aug 2024
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 22, 2026
Sites
1 site added, 1 site removed
Show site
  • CHU Besancon · Besançon, France
Show 1 removed
  • CHU Besancon · Besancon, France
Oct 22, 2026
Primary completion
Aug 20, 2024→Aug 20, 2025 (actual)
Oct 22, 2026
Study completion
Aug 20, 2024→Aug 20, 2025 (actual)
Oct 22, 2026
Enrollment
45 (estimated)→40 (actual)
Oct 22, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41078218 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41078218 ↗
    1 site added, 1 site removed
    Show site
    • CHU Besancon · Besançon, France
    Show 1 removed
    • CHU Besancon · Besancon, France
    Primary completion Aug 20, 2024→Aug 20, 2025 (now actual)
    Study completion Aug 20, 2024→Aug 20, 2025 (now actual)
    Enrollment 45 (estimated)→40 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04818918
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
May 19, 2021
Primary completion
Aug 20, 2025
Completion
Aug 20, 2025
Last update
Oct 22, 2026

Study contacts

Nicolas Meneveau, MD, PhD
principal investigator · Centre Hospitalier Universitaire de Besancon

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion